Skip to main content
Clinical Trials/TCTR20210420006
TCTR20210420006
Completed
Not Applicable

Evaluation of Anti-Inflammatory Effect of Moringa oleifera Lam. and Vernonia cinerea Lozenge in smokers

Thailand Science Research and Innovation (TSRI)0 sites67 target enrollmentStarted: April 20, 2021Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Thailand Science Research and Innovation (TSRI)
Enrollment
67

Overview

Brief Summary

In this study, MO leaf extract, VC extract, MO lozenges, and MO+VC lozenges showed strong antioxidant potential and anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines as IL-6 of inflamed human macrophages. Moreover, lozenges containing MO and MO+VC had a strong effect on reducing gingivitis and oral inflammation in smokers.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to 65 Years (—)
Sex
All

Inclusion Criteria

  • Smokers aged between 18 and 65 years, smoked more than 5 cigarettes/day in the past 6 months, diagnosed by a dentist with mild or moderate oral inflammation, and healthy subjects with no allergic history to any ingredient in the lozenges.

Exclusion Criteria

  • Exclusion criteria included subjects who had a history of disease including diabetes mellitus, cardiovascular, cancer, significant hepatic and renal impairment, neuro\-logic and psychiatric disorder, and immunodeficiency, pregnant or breastfeeding, used drugs including antibiotics, anti\-inflammatory, anticoagulants, anticonvulsants, immunosuppressive drugs within 6 months before the study visit, severe alcoholism or drug addict, and previous use of anti\-inflammation or smoking cessation products within one month.

Investigators

Sponsor
Thailand Science Research and Innovation (TSRI)

Similar Trials